TriangleNCT02418000 · MORE INFO
Limitations, agreements, and source contact
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- certain Agreement
- pi Sponsor Employee
- false
- restrictive Agreement
- false
- limitations And Caveats
- description
- Although E6201 exhibited an acceptable safety profile when administered at doses up to the MTD of 320 mg/m\^2 IV twice weekly, insufficient efficacy was observed during the Phase 1 portion of the study. Thus, the Phase 2a portion was not initiated.
- point Of Contact
- linda.paradiso@spiritaoncology.com
- organization
- Spirita Oncology, LLC
- phone
- +1 (713) 898-8965
- title
- Chief Development Officer
Complete source fields
- certain Agreement
- pi Sponsor Employee
- false
- restrictive Agreement
- false
- limitations And Caveats
- description
- Although E6201 exhibited an acceptable safety profile when administered at doses up to the MTD of 320 mg/m\^2 IV twice weekly, insufficient efficacy was observed during the Phase 1 portion of the study. Thus, the Phase 2a portion was not initiated.
- point Of Contact
- linda.paradiso@spiritaoncology.com
- organization
- Spirita Oncology, LLC
- phone
- +1 (713) 898-8965
- title
- Chief Development Officer
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice